Elevated serum triglyceride levels and long-term mortality in patients with coronary heart disease: The Bezafibrate Infarction Prevention (BIP) registry

Circulation

Volumn 100, Issue 5, 1999, Pages 475-482

  Haim, Moti ^a,b   Benderly, Michal ^b   Brunner, Daniel ^c   Behar, Solomon ^b   Graff, Eran ^c   Reicher Reiss, Henrietta ^b   Goldbourt, Uri ^b,d  

^a MEIR MEDICAL CENTER   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

^c Dept of Internal Medicine C   (Israel)

^d TEL AVIV UNIVERSITY   (Israel)

Author keywords

Coronary disease; Lipoproteins; Mortality

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RISK ASSESSMENT; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0033520018     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.100.5.475     Document Type: Article

References (34)

1. Austin MA. Plasma triglyceride as a risk factor for coronary heart disease: the epidemiologic evidence and beyond. Am J Epidemiol. 1989;129: 249-259.
2. Stampfer MJ, Krauss RM, Ma J, Blanche PJ, Holl LG, Sacks FM, Hennekens CH. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA. 1996;276:882-888.
3. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. Relation of high triglyceride-low HDL cholesterol and LDL cholesterol to the incidence of ischemic heart disease: an 8-year follow-up in the Copenhagen Male Study. Arterioscler Thromb Vasc Biol. 1997;17:1114-1120.
4. Criqui MH, Heiss G, Cohn R, Cowan LD, Suchindran CM, Bangdiwala S, Kritchevsky S, Jacobs DR, Haesook KO, Davis CE. Plasma triglyceride level and mortality from coronary heart disease. N Engl J Med. 1993;328:1220-1225.
5. Manninen V, Tenkanen L, Koskinen P, Huttunen JK, Manttari M, Heinonen OP, Frick H. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Circulation. 1992;85:37-45.
6. Burchfiel CM, Laws A, Benfante R, Goldberg RJ, Hwang LJ, Chiu D, Rodriguez BL, Curb JD, Sharp DS. Combined effects of HDL cholesterol, triglyceride, and total cholesterol concentrations on 18-year risk of atherosclerotic disease. Circulation. 1995;92:1430-1436.
7. Bainton D, Miller NE, Bolton CH, Yarnell JWG, Sweetnam PM, Baker IA, Lewis N, Elwood PC. Plasma triglyceride and high density lipoprotein cholesterol as predictors of ischemic heart disease in British men: the Caerphilly and Speedwell collaborative heart studies. Br Heart J. 1992;68:60-66.
8. Menotti A, Scanga M, Morisi G. Serum triglycerides in the prediction of coronary artery disease (an Italian experience). Am J Cardiol. 1994;73:29-32.
9. Ganziano JM, Hennekens CH, O'Donell CH, Breslow JL, Buring JE, Fasting triglycerides, high density lipoprotein, and risk of myocardial infarction. Circulation. 1997;96:2520-2525.
10. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. Triglyceride concentrations and ischemic heart disease: an eight year follow-up in the Copenhagen male study. Circulation. 1998;97:1029-1036.
11. Austin MA. Plasma triglyceride and coronary heart disease. Arterioscler Thromb. 1991;11:2-14.
12. Lemarche B, Despres JP, Pouliot MC, Prud'homme D, Moorjani S, Lupien PJ, Nadeau A, Tremblay A, Bouchard C. Metabolic heterogeneity associated with high plasma triglyceride or low HDL cholesterol levels in men. Arterioscler Thromb. 1993;13:33-40.
13. The Bezafibrate Infarction Prevention (BIP) Study Group. Lipids and lipoproteins in symptomatic coronary heart disease: distributions, intercorrelations, and significance for risk classification in 6,700 men and 1,500 women. Circulation. 1992;86:839-848.
14. Goldbourt U, Behar S, Reicher-Reiss H, Agmon J, Kaplinsky E, Graff E, Kishon Y, Caspi A, Weisbort J, Mandelzweig L, et al. Rationale and design of a secondary prevention trial of elevating serum high-density lipoprotein cholesterol and reducing triglyceride in patients with clinically manifest atherosclerotic heart disease: the Bezafibrate Infarction Prevention trial. Am J Cardiol. 1993;71:909-915.
15. Criteria Committee, New York Heart Association, Inc. Diseases of the Heart and Blood Vessels: Nomenclature and Criteria for Diagnosis. 6th ed. Boston, Mass: Little Brown & Co; 1964:114.
16. Campeau L. Grading of angina pectoris. Circulation. 1976;54:22. Letter.
17. SAS Institute Inc. SAS/STAT Software: Changes and Enhancements Through Release 6.11. Cary, NC: SAS Institute Inc; 1996.
18. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, Abbott R, Godwin J, Dyer A, Stamler J. Blood pressure, stroke, and coronary heart disease, I: prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990;335: 765-774.
19. Assmann G, Schulte H. The Prospective Cardiovascular Munster study: prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease. Am Heart J. 1988;116:1713-1724.
20. Tenkanen L, Pietila K, Manninen V, Manttari M. The triglyceride issue revisited: findings from the Helsinki Heart Study. Arch Intern Med. 1994;154:2714-2720.
21. Assmann G, Schulte H. The importance of triglycerides: results from the Prospective Cardiovascular Munster (PROCAM) study. Eur J Epidemiol. 1992;8:99-103.
22. Reaven GM. Role of insulin resistance in human disease. Diabetes. 1988;37:1595-1607.
23. Ginsberg HN. Is hypertriglyceridemia a risk factor for atherosclerotic cardiovascular disease? A simple question with a complicated answer. Ann Intern Med. 1997;126:912-914.
24. Design features and baseline characteristics of LIPID (Long-Term Intervention with Pravastatin in Ischemic Disease) study: a randomized trial in patients with previous acute myocardial infarction and/or unstable angina pectoris. Am J Cardiol. 1995;76:474-479.
25. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JMO, Wun CC, Davis BR, Braunwald E, for the Cholesterol And Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-1009.
26. Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease, the PROCAM experience. Am J Cardiol. 1992;70:733-737.
27. Assmann G, Schulte H, Cullen P. New and classical risk factors: the Munster heart study (PROCAM). Eur J Med Res. 1997;16:237-242.
28. Frick MH, Elo O, Happa K, Heinonen OP, Heinasalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V, Maenpaa H, Malkonen M, Manttari M, Norola S, Pasternack A, Pikkarainen J, Romo M, Sjoblom T, Nikkila EA. The Helsinki Heart Study: primary prevention trial with gemfibrozil in middle aged-men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987;317:1237-1245.
29. Tenkanen L, Manttari M, Manninen V. Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil: experience from the Helsinki Heart Study. Circulation. 1995;92:1779-1785.
30. de Faire U, Ericsson CG, Grip L, Nilsson J, Svane B, Hamsten A. Retardation of coronary atherosclerosis: the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) and other angiographic trials. Cardiovasc Drugs Ther. 1997;11(suppl 1):257-263.
31. Ericsson CG, Hamsten A, Nilsson J, Grip L, Svane B, de Faire U. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male post infarction patients. Lancet. 1996;347:849-853.
32. Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand. 1988;223: 405-418.
33. Grundy SM, Balady GF, Criqui MH, Fletcher G, Greenland P, Hiratzka LF, Houston-Miller N, Kris-Etherton P, Krumholz HM, LaRosa J, Ockene IS, Pearson TA, Reed J, Washington R, Smith SC Jr. Guide to primary prevention of cardiovascular diseases: a statement for healthcare professionals from the Task Force on Risk Reduction. Circulation. 1997; 95:2329-2331.
34. Rubins HB, Robins SJ, Iwane MK, Boden WE, Elam MB, Fye CL, Gordon DJ, Schaefer EJ, Schectman G, Wittes JT. Rationale and design of the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Trial (HIT) for secondary prevention of coronary artery disease in men with low high-density lipoprotein cholesterol and desirable low-density lipoprotein cholesterol. Am J Cardial. 1993;71:45-52.